Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
LOADING
|||
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
478.84%
↑ 11453% above average
Average (39q)
-4.22%
Historical baseline
Range
High:478.84%
Low:-560.61%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 478.84% |
| Q2 2025 | -15.31% |
| Q1 2025 | 31.38% |
| Q4 2024 | 24.92% |
| Q3 2024 | -560.61% |
| Q2 2024 | 74.39% |
| Q1 2024 | 52.18% |
| Q4 2023 | -193.31% |
| Q3 2023 | 153.53% |
| Q2 2023 | -58.54% |
| Q1 2023 | 16.09% |
| Q4 2022 | 48.88% |
| Q3 2022 | -46.33% |
| Q2 2022 | -15.42% |
| Q1 2022 | 7.01% |
| Q4 2021 | -26.38% |
| Q3 2021 | -7.89% |
| Q2 2021 | 5.36% |
| Q1 2021 | 17.76% |
| Q4 2020 | 3.85% |
| Q3 2020 | -41.32% |
| Q2 2020 | 1.64% |
| Q1 2020 | 34.02% |
| Q4 2019 | -32.44% |
| Q3 2019 | 4.99% |
| Q2 2019 | -20.65% |
| Q1 2019 | 13.96% |
| Q4 2018 | 13.80% |
| Q3 2018 | -49.96% |
| Q2 2018 | -15.82% |
| Q1 2018 | 0.71% |
| Q4 2017 | -15.69% |
| Q3 2017 | -3.81% |
| Q2 2017 | -10.37% |
| Q1 2017 | 5.00% |
| Q4 2016 | -8.52% |
| Q3 2016 | -15.47% |
| Q2 2016 | 12.47% |
| Q1 2016 | -13.51% |
| Q4 2015 | -18.14% |